Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer

9 months ago

Proprietary T-Bolt™ technology dramatically broadens the benefits of immunotherapy by targeting the entire universe of cancer antigens  Company led by proven industry…

Velocity and Privia Health Enter Partnership to Embed Clinical Research Into Practice Sites

9 months ago

Dr. Paul Evans, Chief Executive and President of Velocity Dr. Paul Evans, Chief Executive and President of VelocityPartnership builds on…

AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer

9 months ago

StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk of breast cancer recurrenceLONDON and…

Psyence Appoints Intellectual Property Expert to Its Board of Directors

9 months ago

TORONTO, July 11, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is…

Iridia Announces Appointment of Buck Watia as Vice President, Corporate Development

9 months ago

Buck Watia to Lead Commercialization of Proprietary DNA Data Storage Technology that Promises to Transform How Customers Manage, Secure and…

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

9 months ago

WILMETTE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing…

Samsung Bioepis Releases its Second US Biosimilar Market Report

9 months ago

Details updated average sales price (ASP) trends and market share across all molecules for which biosimilars are availableIncludes Wholesale Acquisition…

Bright Minds Announces Effective Date of Share Consolidation

9 months ago

VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or…

AlzeCure Publishes New Disease Modifying Data with NeuroRestore ACD856 Against Alzheimer’s and Cognitive Disorders

9 months ago

STOCKHOLM, SWEDEN / ACCESSWIRE / July 11, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…